PRODUCING NATURAL B-CAROTENE FOR CHEMOTHERAPEUTIC USE

生产用于化疗的天然 B-胡萝卜素

• 批准号: 3492926
• 负责人: DAVID J KYLE
• 金额: $ 5万
• 依托单位: MARTEK BIOSCIENCE CORPORATION
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-08-01 至 1992-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3492926
• 关键词: algae; antineoplastics; antioxidants; biosynthesis; carotene; fermentation; isomer

beta-carotene (Provitamin A) has recently been shown to be an effective chemotherapeutic agent in the treatment and prevention of cancer. Moreover, carotenes produced biosynthetically (containing 9-cis isomers) appear to be a more effective antitumor agents than those presently manufactured chemically (all-trans isomers). At present, there is no cost competitive process of biosynthetically producing beta-carotene. We have identified a microalgal species which can be grown under conventional, clean-room, fermentation conditions, and produces a mixture of beta- carotene and gamma-carotene. The gaol of this research project is to produce a pharmaceutical grade beta-carotene under aseptic conditions at a cost competitive with the chemical synthesis route. In Phase I, we shall begin the optimization of the beta-carotene productivity of this microorganism through improvements to the medium composition and the physical parameters of the fermentation. We shall also screen for overproducing clone lines which may have a deregulated biosynthetic pathway. On the basis of these preliminary results we will be able to determine the economic feasibility of the overall approach. During Phase II, the optimization and scale-up development will continue in preparation to establishing a commercial scale process.

β-胡萝卜素（维生素原A）最近已被证明是一种有效的 在治疗和预防癌症中的化学治疗剂。 此外，生物合成产生的胡萝卜素（含有9-顺式异构体） 似乎是一种比目前更有效的抗肿瘤剂 化学制造（全反式异构体）。 目前，没有任何费用 生物合成生产β-胡萝卜素的竞争过程。 我们有 鉴定了可以在常规条件下生长的微藻物种， 洁净室，发酵条件，并产生β- 胡萝卜素和γ-胡萝卜素。 这个研究项目的目标是 在无菌条件下，以 与化学合成路线相比具有成本竞争力。 在第一阶段，我们将 开始优化β-胡萝卜素的生产力， 微生物通过改进培养基组成和 发酵的物理参数。 我们还将筛选 过量生产可能具有失调的生物合成的克隆系， 通路 根据这些初步结果，我们将能够 确定总体方法的经济可行性。 在阶段 二、筹备中继续优化规模化发展 建立一个商业规模的过程。